公开(公告)号：US20180066322A1

公开(公告)日：2018-03-08

申请号：US15721147

申请日：2017-09-29

Applicant: NOVARTIS AG ,  DANA-FARBER CANCER INSTITUTE INC. ,  BROAD INSTITUTE

Inventor： Giordano Caponigro ,  Scott Delach ,  Levi Garraway ,  Zainab Jagani ,  Sunkyu Kim ,  Gregory Kryukov

IPC: C12Q1/68 ,  A61K31/506 ,  A61K31/454 ,  A61K31/519 ,  G01N33/50 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  A61K31/454 ,  A61K31/506 ,  A61K31/519 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/5011 ,  G01N33/57496 ,  G01N2333/4739 ,  G01N2440/14 ,  G01N2500/04 ,  G01N2500/10

Abstract: The invention provides methods of monitoring differential gene expression of biomarkers to determine patient sensitivity to Cyclin Dependent kinase inhibitors (CDKi), methods of determining the sensitivity of a cell to a CDKi, methods of treating a patient with a CDKi and methods of screening for candidate CDKi.

公开(公告)号：US20190046533A1

公开(公告)日：2019-02-14

申请号：US15998710

申请日：2018-08-16

Applicant: Novartis AG

Inventor： Yan Chen ,  Xizhong Huang ,  Sunkyu Kim

IPC: A61K31/519 ,  A61K31/5685 ,  A61K31/551 ,  A61K45/06 ,  A61K31/4439 ,  A61K31/5377 ,  A61K31/5513 ,  A61K31/436 ,  A61K31/4196 ,  A61K31/565 ,  A61K31/138

Abstract: The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20150164897A1

公开(公告)日：2015-06-18

申请号：US14414998

申请日：2013-07-25

Applicant: NOVARTIS AG

Inventor： Giordano Caponigro ,  Darrin Stuart ,  Sunkyu Kim ,  Alice Loo ,  Scott Delach

IPC: A61K31/519 ,  A61K31/4184 ,  A61K31/506

CPC classification number: A61K31/519 ,  A61K31/4184 ,  A61K31/506 ,  A61K2300/00

Abstract: A pharmaceutical combination comprising (a) CDK4/6 inhibitor (b) a B-Raf inhibitor, and optionally (c) a MEK 1/2 inhibitor; combined preparations and pharmaceutical compositions thereof; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Abstract translation: 一种药物组合，其包含（a）CDK4 / 6抑制剂（b）B-Raf抑制剂和任选的（c）MEK 1/2抑制剂; 联合制剂及其药物组合物; 这种组合在增殖性疾病治疗中的应用; 以及治疗患有增殖性疾病的受试者的方法，包括施用治疗有效量的这种组合。

公开(公告)号：US20180207163A1

公开(公告)日：2018-07-26

申请号：US15935294

申请日：2018-03-26

Applicant: Novartis AG

Inventor： Maria Borland ,  Christopher Thomas Brain ,  Shivang Doshi ,  Sunkyu Kim ,  Jianguo Ma ,  Josh Murtie ,  Hong Zhang

IPC: A61K31/519 ,  A61K31/436 ,  A61K45/06

CPC classification number: A61K31/519 ,  A61K31/436 ,  A61K45/06 ,  A61K2300/00

Abstract: A combination of a CDK4/6 inhibitor and an mTOR inhibitor for the treatment of cancer.

公开(公告)号：US09867825B2

公开(公告)日：2018-01-16

申请号：US14651297

申请日：2013-12-16

Applicant: Novartis AG

Inventor： Giordano Caponigro ,  Scott Delach ,  Shivang Doshi ,  Thomas Horn-Spirohn ,  Sunkyu Kim

IPC: A61K31/519 ,  A61K31/4184

CPC classification number: A61K31/519 ,  A61K31/4184 ,  A61K2300/00

Abstract: A combination of a CDK4/6 inhibitor and a MEK inhibitor for the treatment of diseases such as cancer.

公开(公告)号：US09700557B2

公开(公告)日：2017-07-11

申请号：US14414998

申请日：2013-07-25

Applicant: NOVARTIS AG

Inventor： Giordano Caponigro ,  Darrin Stuart ,  Sunkyu Kim ,  Alice Loo ,  Scott Delach

IPC: A61K31/519 ,  A61K31/4184 ,  A61K31/506

CPC classification number: A61K31/519 ,  A61K31/4184 ,  A61K31/506 ,  A61K2300/00

Abstract: A pharmaceutical combination comprising (a) CDK4/6 inhibitor (b) a B-Raf inhibitor, and optionally (c) a MEK 1/2 inhibitor; combined preparations and pharmaceutical compositions thereof; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.